Highest-materiality recent filing
Nu Skin EVP & President of Global Sales Justin Keisel begins medical leave
Justin Keisel, EVP and President of Global Sales, began medical leave effective Aug 17, 2026.
Nu Skin Q2 revenue down 17% to $320M; GAAP EPS -$5.14, adjusted $0.20
Revenue $320.1M, down 17.1% YoY; FX impact -$4.0M.
Nu Skin shareholders approve amended 2024 omnibus incentive plan with 2.85M share increase
Shareholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share reserve by 2,850,000 to 4,859,919 shares.
Nu Skin EVP & Chief Product Officer Hatchett resigns effective May 8
Steven K. Hatchett resigns as EVP and Chief Product Officer due to family health circumstances.
Nu Skin Q1 revenue $320.6M (-12% YoY), EPS $0.04; guides FY rev $1.35-1.50B
Q1 revenue $320.6M, -12% YoY (1.1% FX tailwind); GAAP EPS $0.04, adjusted EPS $0.14 vs $0.23 prior.
Nu Skin closes $175M term loan and $75M revolver in credit refinancing
$175M term loan fully drawn to repay existing credit agreement; $75M revolving facility also available.
Nu Skin CFO James Thomas resigns; Chelsea Lantz named Interim CFO
James Thomas resigned as EVP and CFO effective March 17, 2026, to pursue an outside opportunity.
Nu Skin appoints Chayce Clark as COO; retains CLO role
Clark appointed EVP, COO & CLO effective March 5, 2026; will oversee global ops, sales, product innovation, tech, brand, and legal.
Nu Skin Q4 revenue $370.3M (-16.9% YoY); FY2025 EPS $3.18, adj. $1.27; Q1 2026 outlook weak
Q4 2025 revenue $370.3M, down 16.9% YoY; EPS $0.29 vs $(0.73) prior year.
Nu Skin Q3 revenue $364.2M (-15.3% YoY); EPS $0.34 in line with guidance
Revenue $364.2M, down 15.3% YoY (down 11.5% ex-Mavely); EPS $0.34 vs $0.17 prior year.
Nu Skin Q2 EPS $0.43 beats guidance; raises FY EPS outlook to $3.05-$3.25
Revenue $386.1M, down 12% YoY; EPS $0.43 (adj. $0.21) vs ($2.38) prior year.
Stockholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share authorization by 790,000 shares (30,535,949 for, 1,899,631 against).
Nu Skin Q1 revenue $364.5M at high end of guidance; adj EPS $0.23 excl. Mavely gain
Q1 revenue $364.5M (-12.7% YoY, ~3% FX headwind); GAAP EPS $2.14 includes $176.2M Mavely gain; adjusted EPS $0.23.
Nu Skin director Zheqing (Simon) Shen will not stand for re-election at 2025 annual meeting
Shen informed the company on March 5, 2025, of his decision due to other professional commitments.
Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B
Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.
Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M
Q4 2024 preliminary revenue at high end of company's guidance range.
Nu Skin sells Mavely to Later for $250M; expects ~$207M cash, $10M stock after distributions
Total consideration $230M cash plus $20M in Purchaser common stock; closed January 2, 2025.
Nu Skin Q3 revenue $430.1M (-13.8% YoY), EPS $0.17; guides lower Q4/FY
Q3 revenue $430.1M (-13.8% YoY); customers 831,768 (-15%), paid affiliates 149,264 (-20%).
Nu Skin adopts amended bylaws updating stockholder proposal and nomination procedures
Board approved Sixth Amended and Restated Bylaws effective Oct 31, 2024.
Nu Skin appoints Mark A. Zorko to board; Audit and Nominating committees
Mark A. Zorko appointed as director effective September 10, 2024, increasing board to nine members.
Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).
Nu Skin stockholders approve 2024 Omnibus Incentive Plan, elect directors
Stockholders approved the 2024 Omnibus Incentive Plan, authorizing 1,219,919 new shares plus prior plan carryover.
Nu Skin Q1 revenue $417.3M, down 13%; EPS $(0.01) GAAP; customer base shrinks 19%
Revenue $417.3M, down 13.3% YoY; foreign currency hit of $18.2M; Rhyz revenue up 57.5% to $62.5M.
Andrew Lipman informed Nu Skin on March 15, 2024 of his decision to retire from the Board.
Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B
Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.
Nu Skin adopts amended bylaws aligning with Delaware law and updating stockholder meeting procedures
Bylaws amended to align with current DGCL provisions and certificate of incorporation.
Nu Skin Q4 preliminary revenue slightly above guidance; to present at ICR Conference
Preliminary Q4 2023 revenue slightly above guidance range; driven by ageLOC WellSpa iO launch, China promotions, and Rhyz performance.
Nu Skin Q3 revenue down 7% to $498.8M; GAAP EPS $(0.74); guides FY23 revenue $1.92-1.96B
Q3 revenue $498.8M vs $537.8M prior; GAAP EPS loss $(0.74) including $65.7M inventory write-off.
Nu Skin Q2 revenue $500.3M, down 11% YoY; EPS $0.54; acquires BeautyBio
Revenue $500.3M, -11% YoY; EPS $0.54 vs $0.67 prior year (or $0.77 ex-Grow Tech charges).
Nu Skin appoints James D. Thomas as permanent CFO, replaces interim role
James D. Thomas named Executive VP and CFO effective July 24, 2023; previously served as Interim CFO since March 2023.
Nu Skin stockholders elect all nine director nominees and approve say-on-pay at 2023 annual meeting
All nine director nominees elected; Battle received 42.4M for, Woodbury 42.7M for.
Nu Skin Q1 2023 revenue $481.5M (-20% YoY), EPS $0.23 vs $0.76; reaffirms FY guidance
Revenue fell 20% to $481.5M; GAAP EPS $0.23 declined from $0.76; adjusted EPS $0.37 ex restructuring.
Nu Skin CFO Mark Lawrence resigns; James Thomas named Interim CFO
Mark Lawrence resigns as EVP and CFO effective March 31, 2023; will remain as senior advisor through April.
Nu Skin Q4 revenue down 22% to $522.3M; guides Q1 rev $450-490M
Q4 revenue $522.3M (-22% YoY); full-year $2.23B (-17%); customers fell 16% to 1.15M.
Nu Skin grants $2.5M RSUs to EVP/GC Chayce Clark; salary to rise to $550k
Compensation Committee approved $2,500,000 in restricted stock units to Chayce D. Clark on Dec. 20, 2022.
Nu Skin Q3 2022 revenue $537.8M (-16% YoY); GAAP EPS $(0.51), non-GAAP $0.47
Revenue $537.8M, down 16% YoY (7% FX headwind); gross margin 67.7% (72.7% ex-restructuring).
Nu Skin Q2 revenue falls 20% to $560.6M; cuts FY guidance, plans restructuring
Revenue of $560.6M, down 20% YoY; adjusted EPS of $0.77 (ex. Grow Tech) vs $1.15 prior year.
Nu Skin prelim Q2 revenue $557-562M, soft due to China COVID, EMEA conflict
Estimated Q2 2022 revenue between $557 and $562 million, softer than expected.
Nu Skin enters into $900M credit facility; $400M term loan + $500M revolver, 5-year term
New credit agreement provides a $400M term loan and a $500M revolving credit facility, each with a five-year term.
All nine director nominees elected; votes for ranged from 37.3M (Lipman) to 40.9M (Shen), with ~3.0M broker non-votes.
Nu Skin EVP Connie Tang takes temporary medical leave; CEO to lead her organization
Connie Tang, EVP and Chief Global Growth and Customer Experience Officer, begins medical leave May 31, 2022.
Nu Skin Q1 revenue $604.9M (-11% YoY), EPS $0.76 (-16%); lowers FY22 guidance
Revenue $604.9M, down 11% YoY; EPS $0.76 vs $0.91; gross margin 73.3% vs 74.8%.
Nu Skin reports 2021 adjusted EPS up 14% to $4.14; revenue up 4%; unveils Nu Vision 2025 plan
Total revenue increased 4% in 2021; adjusted EPS grew 14% to $4.14 (reported EPS down 21% to $2.86 due to restructuring).
Nu Skin Q4 rev $673M (-10%), adj EPS $1.11; FY22 guidance rev $2.66-2.77B, EPS $4.05-4.45
Q4 2021 revenue $673.4M, down 10% YoY; customers down 12% to 1.37M, sales leaders down 13% to 61,515.
Nu Skin CEO Ryan Napierski outlines Nu Vision 2025 strategy in New Year message
CEO emphasizes EmpowerME personalized beauty/wellness and IoT devices to disrupt $1.2T beauty & wellness market.
Nu Skin to exit Grow Tech segment, expects $52-60M in pre-tax charges
Decision to wind down controlled-environment agriculture business, focused on feed industry.
Nu Skin Q3 revenue $641.2M (-9% YoY), EPS $0.97 (-10%); cuts Q4 outlook
Q3 revenue $641.2M, down 9% YoY; EPS $0.97 vs $1.08 in prior year.
Nu Skin estimates Q3 revenue $637-642M, below expectations due to delta variant disruptions
Estimated Q3 2021 revenue between $637M and $642M, softer than anticipated.
Nu Skin appoints Ryan Napierski as CEO; compensation package disclosed: $900K salary, RSUs, PSOs
CEO Ryan Napierski's annual salary set at $900,000 effective Sept 1, 2021.
Nu Skin Q2 revenue $704.1M, EPS $1.15 (+42% YoY), raises FY EPS guidance
Revenue $704.1M (+15% YoY, +6% FX); EPS $1.15 vs $0.81 prior year (+42%).
Steven K. Hatchett notified the Company that, due to family health circumstances, he determined to resign from his position as Executive Vice President and Chief Product Officer, effective as of May 8, 2026.
On March 5, 2025, Zheqing (Simon) Shen informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided not to stand for re-election to the Company’s Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders due to other professional commitments.
On September 10, 2024, the Board of Directors (the “Board”) of Nu Skin Enterprises, Inc. (the “Company”) appointed Mark A. Zorko as a director of the Company
On March 15, 2024, Andrew Lipman informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided to retire from the Company’s Board of Directors (the “Board”) and will not stand for re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders.
Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.
Connie Tang notified the Company that, due to family health reasons, she determined to resign from her position as Executive Vice President and Chief Global Growth and Customer Experience Officer, effective October 31, 2023.
On July 24, 2023, following a search that included internal and external candidates, the Company’s Board of Directors appointed James D. Thomas as Executive Vice President and Chief Financial Officer on a permanent basis.
On March 24, 2023, Mark H. Lawrence notified Nu Skin Enterprises, Inc. (the “Company”) of his resignation from his position as Executive Vice President and Chief Financial Officer.
On March 30, 2023, the Company’s Board of Directors appointed James D. Thomas, the Company’s Senior Vice President and Chief Accounting Officer, as Interim CFO, effective upon Mr. Lawrence’s departure as CFO.
Max materiality 0.85 · Median 0.65 · Most common event earnings